Formycon AG (WBO:FYB) Other Stockholders Equity: €0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:FYB Formycon AG WBO:FYB
39 GF Score
Price €18.30
GF Value €37.04
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Formycon AG Other Stockholders Equity?

Formycon AG WBO:FYB +0.22% 39 Other Stockholders Equity is €0.00 Mil as of Dec. 2025. GuruFocus rates WBO:FYB with a GF Score™ of 39/100 and a GF Value™ of €37.04 (Possible Value Trap). The stock has 5 warning signs investors should review.

Formycon AG's Other Stockholders Equity for the quarter that ended in Dec. 2025 was €0.00 Mil.

Formycon AG's quarterly Other Stockholders Equity declined from Dec. 2024 (€0.00 Mil) to Jun. 2025 (€0.00 Mil) and declined from Jun. 2025 (€0.00 Mil) to Dec. 2025 (€0.00 Mil).

Formycon AG's annual Other Stockholders Equity increased from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€0.00 Mil) but then declined from Dec. 2024 (€0.00 Mil) to Dec. 2025 (€0.00 Mil).

Formycon AG Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Formycon AG's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Formycon AG Other Stockholders Equity Chart

Formycon AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Formycon AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
WBO:FYB
39GF Score
Formycon AG WBO:FYB
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Formycon AG Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €0.00 Mil mean?
Formycon AG (WBO:FYB) has a Other Stockholders Equity of €0.00 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Formycon AG and its competitors.
Is Formycon AG's Other Stockholders Equity too high?
Formycon AG's current Other Stockholders Equity is €0.00 Mil. Overall, Formycon AG has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Formycon AG's Other Stockholders Equity compare to VRTX and REGN?
Formycon AG's Other Stockholders Equity of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Formycon AG and its competitors. Formycon AG's current Other Stockholders Equity is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Formycon AG stock overvalued right now?
Based on GuruFocus' analysis, Formycon AG (WBO:FYB) is currently considered Possible Value Trap. The stock's GF Value™ is €37.04, compared to a current price of €18.30 — trading 50.6% below its estimated fair value. The current Other Stockholders Equity is €0.00 Mil. Formycon AG's overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Formycon AG (WBO:FYB), the current Other Stockholders Equity is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Formycon AG (WBO:FYB) Overvalued in 2026?

Based on GuruFocus' analysis, Formycon AG stock appears to be undervalued. The current stock price of €18.30 is trading 50.6% below its estimated GF Value™ of €37.04. GuruFocus considers Formycon AG to be Possible Value Trap.

Key valuation signals for WBO:FYB:

  • Other Stockholders Equity: €0.00 Mil
  • GF Value™: €37.04 vs. price of €18.30 (50.6% below fair value)
  • GF Score™: 39/100 with 5 warning signs

No single metric tells the full story. See the WBO:FYB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Formycon AG Business Description

Other Exchanges 0W4N:UKFYB:Germany
Address Fraunhoferstrasse 15, Martinsried, Planegg, BY, DEU, 82152
Formycon AG is an independent developer of high-quality biosimilars, which are follow-on products to biopharmaceutical drugs. The Company focuses on expanding and further developing its scalable biosimilar platform, which includes approved and pipeline products across ophthalmology, immunology, and immuno-oncology. Its key products include FYB201 (ranibizumab), FYB202 (ustekinumab), FYB203 (aflibercept), FYB206 (pembrolizumab), and FYB208 (dupilumab), along with additional biosimilar candidates in various stages of development. The Company generates maximum revenue from Switzerland.
39GF Score

Get the complete analysis for WBO:FYB

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€18.30
Price
€37.04
GF Value